ProMIS Neurosciences September 2026 Conferences
Analysis based on 8 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026
The announcement of conference participation is a routine investor relations activity with minimal direct market impact. It may modestly increase visibility and investor engagement for ProMIS Neurosciences, potentially supporting its stock price in the near term.
ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines for neurodegenerative diseases, announced its participation in several investor conferences and events in September 2026. The company will present at the Cantor Global Healthcare Conference (September 9-11), Moody s Ratings Disruptive Growth & Life Sciences Conference (September 9-10), H.C. Wainwright 28th Annual Global Investment Conference (September 14-16), and Roth Healthcare Opportunities Conference (September 29), all in New York City. On September 21, World Alzheimer's Day, ProMIS will mark the occasion at the Nasdaq Tower. During these events, CEO Neil Warma, CMO Larry Altstiel, and VP of IR Carie Pierce will discuss the EpiSelect platform and PMN310, the lead candidate in the ongoing PRECISE-AD Phase 1b trial for early Alzheimer's disease. The company reported blinded 6-month interim data from the trial in July 2026, with 12-month topline data expected in early 2027.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard